Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy-Reference-Cited by-同舟云学术

Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy

Published:2021-05-01 Issue:5 Volume:31 Page:821-828
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Vannucchi Guia¹,Campi Irene¹,Covelli Danila²,Currò Nicola³,Lazzaroni Elisa²,Palomba Andrea⁴,Soranna Davide⁵,Zambon Antonella⁴,Fugazzola Laura¹,Muller Ilaria²,Guastella Claudio⁶,Salvi Mario²

Affiliation:

1. Endocrine and Metabolic Department, Istituto Auxologico Italiano IRCCS, Milano, Italy.

2. Department of Clinical Sciences and Community Health, Graves' Orbitopathy Center, Endocrinology, Milan, Italy.

3. Department of Ophthalmology, Fondazione IRCCS Cà Granda, Milan, Italy.

4. Division of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.

5. Istituto Auxologico Italiano IRCCS, Milan, Italy.

6. Department of Otolaryngology, Fondazione IRCCS Cà Granda, Milan, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2020.0269

Reference33 articles.

1. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement

2. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

3. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study